key: cord-0704286-0slywdik
authors: Hassan, Ahmed O.; Case, James Brett; Winkler, Emma S.; Thackray, Larissa; Kafai, Natasha M.; Bailey, Adam L.; McCune, Broc T.; Fox, Julie M.; Chen, Rita E.; Al Soussi, Wafaa B.; Turner, Jackson S.; Schmitz, Aaron J.; Lei, Tingting; Shrihari, Swathi; Keeler, Shamus P.; Fremont, Daved H.; Greco, Suellen; McCray, Paul B.; Perlman, Stanley; Holtzman, Michael J.; Ellebedy, Ali H.; Diamond, Michael S.
title: A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies
date: 2020-06-10
journal: Cell
DOI: 10.1016/j.cell.2020.06.011
sha: 7fc7186f7204e378f3a6737423ab5b6af621a42a
doc_id: 704286
cord_uid: 0slywdik

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic with millions of human infections. One limitation to the evaluation of potential therapies and vaccines to inhibit SARS-CoV-2 infection and ameliorate disease is the lack of susceptible small animals in large numbers. Commercially available laboratory strains of mice are not readily infected by SARS-CoV-2 because of species-specific differences in their angiotensin-converting enzyme 2 (ACE2) receptors. Here, we transduced replication-defective adenoviruses encoding human ACE2 via intranasal administration into BALB/c mice and established receptor expression in lung tissues. hACE2-transduced mice were productively infected with SARS-CoV-2, and this resulted in high viral titers in the lung, lung pathology, and weight loss. Passive transfer of a neutralizing monoclonal antibody reduced viral burden in the lung and mitigated inflammation and weight loss. The development of an accessible mouse model of SARS-CoV-2 infection and pathogenesis will expedite the testing and deployment of therapeutics and vaccines.

via an intranasal route. None of the mice tested had weight loss over the first week, and lungs 100 harvested at 10 days post-infection (dpi) showed very low levels of viral RNA (Fig 1A-B) . The 

However, SARS-CoV also enters the brain in these hACE2-transgenic mice, and infection 110 results in transneuronal spread and ultimately death due to central nervous system injury and 111 dysfunction (Menachery et al., 2016; Netland et al., 2008) . Since these hACE2-Tg mice are not 112 yet widely available for drug and vaccine testing, we evaluated an alternative strategy in which 113 hACE2 is transiently expressed following transduction with an adenoviral vector, akin to an 114 approach that rendered mice susceptible to MERS-CoV infection by introducing DPP4 (Zhao et expressing human Ad5, AdV-hACE2) (Fig 1C) . Some of the animals received an anti-Ifnar1 7 monoclonal antibody (mAb MAR1-5A3, 2 mg via intraperitoneal injection) to transiently inhibit 119 type I IFN signaling and possibly enhance SARS-CoV-2 infection. We detected hACE2 mRNA 120 by qRT-PCR (Fig 1D) and by in situ hybridization in cells of the lungs including bronchiolar 121 epithelial cells and pneumocytes (Fig 1E) with peak mRNA expression occurring about five 122 days after administration.

In an attempt to maximize infectivity and pathogenesis, BALB/c mice were inoculated 124 initially via intranasal and intravenous routes with 10 5 focus-forming units (FFU) of SARS-CoV-2 125 five days after AdV-hACE2 transduction (Fig 2A) . In contrast to mice transduced only with AdV-126 hACE2, animals administered AdV-hACE2 and inoculated with SARS-CoV-2 had weight loss 127 during the first week (10 to 25%, Fig 2B) . More weight loss was observed in the SARS-CoV-2-128 infected mice that also received anti-Ifnar1 mAb treatment. High levels of SARS-CoV-2 129 infectious virus (by plaque assay) and viral RNA were detected in lung tissue homogenates at 4 130 dpi, whereas lower levels were present in other tissues (e.g., heart, spleen, and brain) and 131 virtually none was measured in kidney, gastrointestinal tract tissues, or in serum (Fig 2C-D) . viral RNA levels waned by days 8 and 10 dpi (~1,000-fold reduction), they were still readily 8 detected in all cohorts of AdV-hACE2-transduced, SARS-CoV-2-infected mice (Fig 2H) . The 145 high levels of SARS-CoV-2 infection in the lung of AdV-hACE2 transduced mice at 4 dpi were 146 confirmed by viral RNA in situ hybridization, with prominent staining observed in epithelial cells 147 lining the bronchioles and alveoli (Fig 2I) . Even in the absence of anti-Ifnar1 mAb treatment, 148 SARS-CoV-2 RNA was readily detected in lung sections.

We evaluated the impact of SARS-CoV-2 infection on lung histopathology after staining 150 with hematoxylin and eosin (H & E). At 4 dpi, mice transduced with recombinant AdV-hACE2 151 alone showed mild immune cell infiltration in peribronchiolar, perivascular, and alveolar sites 152 compared to untreated mice (Fig 3A-B) . At this early time point, these changes were similar in 153 mice also infected with SARS-CoV-2 with or without additional treatment with anti-Ifnar1 154 antibody (Fig 3B) . By 8 dpi, mice given AdV-hACE2 alone showed only focal perivascular 155 inflammation that varied little from the untreated control mice (Fig 3C) . However, at this later 

To assess the utility of this model for evaluating possible therapeutics, we passively 168 transferred to anti-Ifnar1-antibody treated, AdV-hACE2 transduced BALB/c mice a single dose 169 (10 mg/kg) of an anti-SARS-CoV-2 mAb 1B07 or isotype control mAb one day before intranasal 9 SARS-CoV-2 inoculation (Fig 4A) . The 1B07 mAb is a chimeric mouse Fv-human Fc (IgG1) 171 antibody that was generated after immunization of C57BL/6J mice with SARS-CoV-2 S protein, Fig 5A) . We also observed lower levels of SARS-CoV-180 2 RNA at distant tissue sites (e.g., heart and spleen) (Fig 4F-G) . Finally, at 4 dpi, lower levels of 181 several pro-inflammatory cytokines and chemokines (IL-6, CCL2, CCL5, CXCL10, CXCL11, 182 IFN-λ, and IFN-β) were detected in bulk lung homogenates from mice treated with 1B07 183 compared to the isotype control mAb (Fig 4H) , and this phenotype correlated with decreased 184 immune cell infiltrates in the lungs at 6 dpi in animals treated with 1B07 ( Fig 5B) . These data 

Further model refinement is planned using additional laboratory mouse strains (Boon et 

When used in combination with our generated primer-probe set and a known amount of the 413 plasmid control, N gene copy-numbers could be determined down to 10 copies per reaction.

For hACE2 

Tocilizumab for the Treatment of 464

Severe COVID-19

SARS-CoV-2 Vaccines: Status Report

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

COVID-19 473 autopsies

H5N1 influenza virus pathogenesis in genetically diverse mice is 477 mediated at the level of viral load

Simulation of the clinical and pathological manifestations of 481

COVID-19) in golden Syrian hamster model: implications for 482 disease pathogenesis and transmissibility

Wild-type and innate 485 immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus

Distinct Roles of Interferon Alpha 490 and Beta in Controlling Chikungunya Virus Replication and Modulating Neutrophil-Mediated 491 Inflammation

Prophylactic and postexposure efficacy 495 of a potent human monoclonal antibody against MERS coronavirus

Longitudinal Analysis of the Human B 500 Cell Response to Ebola Virus Infection

Covid-19: identifying and isolating asymptomatic people helped eliminate virus 503 in Italian village

MUSCLE: multiple sequence alignment with high accuracy and high 506 throughput

Interferon-λ Mediates

Complement associated microvascular injury and thrombosis in the 561 pathogenesis of severe COVID-19 infection: a report of five cases

Enhanced isolation of SARS-CoV-2 by TMPRSS2-565 expressing cells

Lethal infection of K18-hACE2 mice infected 569 with severe acute respiratory syndrome coronavirus

SARS-like WIV1-CoV poised 573 for human emergence

Evaluation of the concentration and 576 bioactivity of adenovirus vectors for gene therapy

Respiratory disease 580 and virus shedding in rhesus macaques inoculated with SARS-CoV-2

Severe acute 583 respiratory syndrome coronavirus infection causes neuronal death in the absence of 584 encephalitis in mice transgenic for human ACE2

Interferon Signaling: Passage for Diverse Biologic Outcomes

The Collaborative Cross: A Systems Genetics 590 Resource for Studying Host-Pathogen Interactions

Deficient IFN signaling by myeloid cells leads to 594 MAVS-dependent virus-induced sepsis

Dipeptidyl peptidase 4 is a functional receptor for the 598 emerging human coronavirus-EMC

Pharmacologic 601 Treatments for Coronavirus Disease 2019 (COVID-19): A Review

Broad-spectrum antiviral GS-5734 605 inhibits both epidemic and zoonotic coronaviruses

specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo 610 hydrodynamic transfection

Type I interferons link viral infection 618 to enhanced epithelial turnover and repair

An efficient method to make human 622 monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus

Receptor recognition by novel 626 coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS

A human monoclonal antibody 630 blocking SARS-CoV-2 infection

Remdesivir in adults with severe COVID-19: a randomised, double-blind

A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-638

Rapid generation of a mouse model for 642

Middle East respiratory syndrome

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, 646 China: a retrospective cohort study

A Novel Coronavirus from Patients with Pneumonia in China

Laboratory mice transduced with adenoviruses encoding human ACE2 are permissive for SARS-CoV-2 and develop pneumonia. Passive transfer of a neutralizing monoclonal antibody reduces lung infection, inflammation, and disease.